Board of Directors
Dr. Corrigan has served as our President and Chief Executive Officer since January 2010. Dr. Corrigan joined U.S.-based specialty pharmaceutical company Sepracor Inc. in 2003 and served as their Executive Vice President, Research and Development until December 2009. Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn Inc., most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Prior to joining the pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina School of Medicine, focusing on psychoneuroendocrinology. Dr. Corrigan serves on the board of directors of Cubist Pharmaceuticals, Inc. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and subsequently received specialty training in psychiatry at Maine Medical Center and Cornell University.
From April 1985 until January 1997, Ms. Crawford served as Chief Operating Officer of Healthsource, Inc., a publicly held managed care organization headquartered in New Hampshire. During her tenure at Healthsource, Inc., Ms. Crawford held a variety of positions and responsibilities; including leading that company’s Northern Region operations and marketing efforts. Since January 1997, Ms. Crawford has been a healthcare consultant in New Hampshire. Ms. Crawford serves on the board of directors for Hologic, Inc., Exact Sciences Corporation, Insulet Corporation and Universal American Corp. Ms. Crawford holds a B.A. in English from Smith College and an M.S. in communications from Boston University.
Mr. Foley is currently a Managing Director at MPM Asset Management LLC, or MPM. Since joining MPM in 1999, Mr. Foley has been actively involved in numerous investments including a part-time engagement as Chief Operating Officer for Centagenetix Inc. during its start-up phase and Vice President, Business Development for AVEO Pharmaceuticals, Inc. Prior to joining MPM, Mr. Foley worked in business development at Genentech, Inc. and management consulting with Arthur D. Little. Mr. Foley serves on the board of directors of multiple private companies. Mr. Foley holds a B.S. in chemistry from MIT and an M.B.A. from Harvard Business School.
Mr. Haydu has served as a member of the Zalicus Board of Directors since August 2004 and as Chairman of the Board of Directors since February 2009. Mr. Haydu is a professional director and consultant to public and private businesses. Mr. Haydu currently serves as a director and Chairman of the Audit Committee of iParty Corp. and serves on the board of directors of multiple private companies. Mr. Haydu holds a B.A. in economics from Muhlenberg College.
Dr. Hunter has been the Interim Chief Executive Officer of Cardiome Pharma Corp., a public pharmaceutical company, since July 2012. Dr. Hunter founded Angiotech Pharmaceuticals, Inc., a publicly held pharmaceutical and medical device company, in November 1992 and served as its President and Chief Executive Officer until October 2011. Dr. Hunter serves as a director of Cardiome Pharma Corp. Dr. Hunter holds a B.Sc. from McGill University, and an M.Sc. and M.D. from the University of British Columbia.
Dr. Kauffman has been the President and Chief Executive Officer of Karyopharm Therapeutics Inc. since January 2011 and has been a Science Advisor to Bessemer Venture Partners since 2008. Dr. Kauffman was the Chief Medical Officer of Onyx Pharmaceuticals from January 2010 until December 2010, was the Chief Medical Officer of Proteolix, Inc. from April 2009 until its acquisition by Onyx in November 2009 and was the President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. until July 2008. Dr. Kauffman joined Predix Pharmaceuticals, Inc., the predecessor to EPIX, in September 2002, as President and Chief Executive Officer. From 1997 to 2002, he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals, Inc., including Vice President, Medicine and VELCADE Program Leader as well as co-founder and Vice President of Medicine at Millennium Predictive Medicine, a wholly-owned subsidiary of Millennium. Dr. Kauffman also served as Medical Director at Biogen Corporation (now Biogen Idec). Dr. Kauffman serves on the board of directors for Verastem, Inc. Dr. Kauffman received an M.D. and Ph.D. in molecular biology and biochemistry from Johns Hopkins and holds a B.A. in biochemistry from Amherst College. Dr. Kauffman trained in internal medicine at Beth Israel Deaconess and Massachusetts General Hospitals. He is board certified in internal medicine.
From October 1999 to March 2007, Mr. O'Shea was President and Chief Operating Officer at Sepracor Inc. where he was responsible for successfully building that organization's commercial infrastructure. From April to August 2007, Mr. O'Shea served as Sepracor's Vice Chairman. Prior to Sepracor, Mr. O'Shea was Senior Vice President of Sales and Marketing and Medical Affairs for Zeneca Pharmaceuticals, a business unit of Zeneca Inc. While at Zeneca, he also held several management positions of increasing responsibility in international sales and marketing in the U.S. and U.K. Mr. O'Shea is past Chairman of the National Pharmaceutical Council and serves on the board of directors of BTG plc and MAP Pharmaceuticals, Inc. Mr. O'Shea is a graduate of Liverpool Lord Byron University. He also received an honors degree in applied physics from the Institute of Physics.